Question 1

My newborn screened positive for a lipid metabolism disorder. What confirmatory tests are needed, and how quickly should treatment start?

Accepted Answer

positive newborn screen usually triggers a confirmatory quantitative enzyme assay (e.g., acid β‑glucosidase activity for Gaucher disease) and targeted genetic sequencing to identify pathogenic variants. Once the diagnosis is confirmed—often within 2‑4 weeks—early treatment such as enzyme replacement therapy (ERT) or substrate reduction therapy can be initiated, especially for disorders like Fabry or Pompe disease where early intervention improves neuro‑cognitive and cardiac outcomes.

Question 2

My adult brother was diagnosed with Tay‑Sachs disease. As a potential carrier, what reproductive options are available to avoid having an affected child?

Accepted Answer

Carrier testing for the HEXA gene can confirm your status. If you are a carrier, options include preimplantation genetic diagnosis (PGD) with in‑vitro fertilization to select embryos without the disease‑causing mutations, prenatal diagnostic testing (chorionic villus sampling or amniocentesis) to determine fetal status, or using donor gametes (egg or sperm) that are mutation‑free. Genetic counseling is essential to discuss success rates, costs, and ethical considerations.

Question 3

We have a family history of familial hypercholesterolemia. How can we determine if my children are carriers, and what preventive steps are recommended?

Accepted Answer

Begin with a lipid panel for each child after age 2 years; markedly elevated LDL‑C (>190 mg/dL) suggests homozygous disease, while moderate elevations (130‑190 mg/dL) may indicate heterozygosity. Genetic testing for LDLR, APOB, or PCSK9 mutations provides definitive carrier status. If a pathogenic variant is found, start lifestyle counseling (low‑saturated‑fat diet, regular activity) and consider early statin therapy per pediatric guidelines (usually ≥8 years old) to reduce long‑term atherosclerotic risk.

Question 4

I was told I have a rare lipid storage disorder with no cure. Are there any dietary measures that can slow disease progression?

Accepted Answer

While enzyme replacement or substrate‑reduction drugs are the main disease‑modifying therapies, a low‑fat, low‑cholesterol diet may reduce the substrate load for some disorders (e.g., Niemann‑Pick type C). Emphasize lean proteins, non‑starchy vegetables, and fruits, and avoid high‑fat dairy, fried foods, and processed snacks. In certain conditions, medium‑chain triglyceride (MCT) oil can provide an alternative energy source that bypasses defective long‑chain fatty‑acid pathways, but this should only be used under supervision of a metabolic specialist.

Lipid Metabolism Disorders

Overview

Understanding Lipid Disorders

Diagnosis and Management

Frequently Asked Questions